Study of Blood Samples From Patients With Malignant Melanoma, Metastatic Breast Cancer, Advanced Lung Cancer, Pancreatic Cancer, or Colorectal Cancer
This study is currently recruiting participants.
Verified October 2012 by ICORG- All Ireland Cooperative Oncology Research Group
Sponsor:
ICORG- All Ireland Cooperative Oncology Research Group
Information provided by (Responsible Party):
ICORG- All Ireland Cooperative Oncology Research Group
ClinicalTrials.gov Identifier:
NCT00974610
First received: September 9, 2009
Last updated: October 19, 2012
Last verified: October 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in peptides and proteins and identify biomarkers related to cancer.
PURPOSE: This research study is looking at blood samples from patients with malignant melanoma, metastatic breast cancer, advanced lung cancer, pancreatic cancer, or colorectal cancer.
| Condition |
|---|
|
Breast Cancer Colorectal Cancer Lung Cancer Melanoma (Skin) Pancreatic Cancer |
| Study Type: | Observational |
| Study Design: | Time Perspective: Prospective |
| Official Title: | Collaborative Project on Potential Serum Markers for Malignant Melanoma, Metastatic Breast, Advanced Lung Pancreatic Carcinoma and Colorectal Cancer |
Resource links provided by NLM:
Genetics Home Reference related topics:
breast cancer
MedlinePlus related topics:
Breast Cancer
Cancer
Colorectal Cancer
Lung Cancer
Melanoma
Pancreatic Cancer
U.S. FDA Resources
Further study details as provided by ICORG- All Ireland Cooperative Oncology Research Group:
Primary Outcome Measures:
- Detection of peptide and protein markers in serum [ Time Frame: Ongoing ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Identification of the protein/peptide involved [ Time Frame: Ongoing ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 300 |
| Study Start Date: | August 2008 |
| Estimated Primary Completion Date: | June 2013 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
| Breast |
| Lung |
| Melanoma |
| Pancreatic |
| Colorectal |
Detailed Description:
OBJECTIVES:
Primary
- To assess which potential peptide and protein markers produced by human melanoma, lung, breast, pancreatic, and colorectal cell lines may be detectable in serum of patients from these five disease groups.
Secondary
- To conduct further extensive investigation with respect to identification of the protein/peptide involved, determination of specificity for each cancer, and development of more sensitive assays to look for such markers in a wider population of patients, including those undergoing therapy.
OUTLINE: This is a multicenter study.
Blood samples are collected before surgical intervention or treatment to assess peptide and protein markers.
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Study Population
5 different tumour types
Criteria
DISEASE CHARACTERISTICS:
Diagnosis of 1 of the following advanced metastatic malignancies:
- Malignant melanoma
- Lung cancer
- Breast cancer
- Pancreatic carcinoma
- Colorectal cancer
- Advanced and/or metastatic disease
- Hormone receptor status not specified
PATIENT CHARACTERISTICS:
- Menopausal status not specified
PRIOR CONCURRENT THERAPY:
- Not specified
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00974610
Locations
| Ireland | |
| Cork University Hospital | Recruiting |
| Cork, Ireland | |
| Contact: Contact Person 353-21-492-1301 | |
| Mercy University Hospital | Recruiting |
| Cork, Ireland | |
| Contact: Contact Person 021-4271971 | |
| Adelaide and Meath Hospital, Dublin Incorporating the National Children's Hospital | Recruiting |
| Dublin, Ireland, 24 | |
| Contact: Contact Person 353-1-414-2012 | |
| St. James's Hospital | Recruiting |
| Dublin, Ireland, 8 | |
| Contact: Contact Person 353-1-410-3545 | |
| Beaumont Hospital | Recruiting |
| Dublin, Ireland, 9 | |
| Contact: Contact Person 353-21-492-1301 | |
| Mater Private Hospital | Recruiting |
| Dublin, Ireland | |
| Contact: Contact Person 01 885 8888 | |
| Mater Misericordiae University Hospital | Recruiting |
| Dublin, Ireland, 7 | |
| Contact: Contact Person 353-1-858-569 | |
| St. Vincent's University Hospital | Recruiting |
| Dublin, Ireland, 4 | |
| Contact: Contact Person 353-1-209-4895 | |
| St Luke's Hospital | Active, not recruiting |
| Dublin, Ireland | |
| University College Hospital | Recruiting |
| Galway, Ireland | |
| Contact: Contact Person 353-91-544-805 | |
| Letterkenny General Hospital | Recruiting |
| Letterkenny, Ireland | |
| Contact: Contact Person consumer.serviceslgh@hse.ie | |
| Mid-Western Cancer Centre at Mid-Western Regional Hospital | Recruiting |
| Limerick, Ireland, 0009 | |
| Contact: Contact Person 353-61-482-542 | |
| Waterford Regional Hospital | Recruiting |
| Waterford, Ireland | |
| Contact: Contact Person 353-51-842-562 | |
Sponsors and Collaborators
ICORG- All Ireland Cooperative Oncology Research Group
Investigators
| Principal Investigator: | Martin Clynes | National Institute for Cellular Biotechnology at Dublin City University |
More Information
Additional Information:
No publications provided
| Responsible Party: | ICORG- All Ireland Cooperative Oncology Research Group |
| ClinicalTrials.gov Identifier: | NCT00974610 History of Changes |
| Other Study ID Numbers: | CDR0000644159, ICORG-07-12, EU-20949 |
| Study First Received: | September 9, 2009 |
| Last Updated: | October 19, 2012 |
| Health Authority: | Ireland: Irish Medicines Board |
Keywords provided by ICORG- All Ireland Cooperative Oncology Research Group:
|
stage IV non-small cell lung cancer recurrent non-small cell lung cancer extensive stage small cell lung cancer recurrent small cell lung cancer stage IV breast cancer recurrent breast cancer male breast cancer stage III pancreatic cancer |
stage IV pancreatic cancer recurrent pancreatic cancer stage IV colon cancer recurrent colon cancer stage IV rectal cancer recurrent rectal cancer stage IV melanoma recurrent melanoma |
Additional relevant MeSH terms:
|
Breast Neoplasms Colorectal Neoplasms Lung Neoplasms Pancreatic Neoplasms Neoplasms by Site Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type |
Neoplasms, Nerve Tissue Endocrine Gland Neoplasms Melanoma Breast Diseases Skin Diseases Digestive System Diseases Gastrointestinal Diseases Colonic Diseases Intestinal Diseases Rectal Diseases Lung Diseases Respiratory Tract Diseases Nevi and Melanomas Pancreatic Diseases Endocrine System Diseases |
ClinicalTrials.gov processed this record on May 19, 2013